Overview

Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

Status:
Completed
Trial end date:
2017-06-08
Target enrollment:
Participant gender:
Summary
This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis.
Phase:
Phase 1
Details
Lead Sponsor:
Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co.,Ltd.
Collaborator:
Tigermed Consulting Co., Ltd